Intravenous bisphosphonate-related osteonecrosis of the jaws: Influence of coadjuvant antineoplastic treatment and study of buccodental condition

Maria Margaix-Muñoz 1, José Bagán 2, Rafael Poveda-Roda 3

1 Associate Professor of Oral Medicine. Oral Medicine Unit. Department of Stomatology. University of Valencia
2 Chairman of Oral Medicine. Oral Medicine Unit. Department of Stomatology. University of Valencia. Head of the Department of Stomatology and Maxillofacial Surgery. Valencia University General Hospital
3 Staff physician. Department of Stomatology and Maxillofacial Surgery. Valencia University General Hospital

Correspondence:
Unidad de Medicina Bucal. Departamento de Estomatología
Facultad de Medicina y Odontología
C/ Gascó Oliag, 1
46010 Valencia Spain
maria.margaix@uv.es

Received: 27/06/2012
Accepted: 07/07/2012

Abstract
Objectives: To determine whether coadjuvant antineoplastic treatment can influence the number and size of bone exposures among patients with intravenous bisphosphonate-related osteonecrosis of the jaws (iBRONJ), and to analyze the buccodental condition of these patients.

Material and methods: The study sample comprised 67 patients with iBRONJ, 53 patients without iBRONJ receiving treatment with intravenous bisphosphonates, and 36 healthy subjects. In all three groups, measurements were made of the CAO index and of resting whole saliva and stimulated whole saliva. In the patients with iBRONJ, the size (cm) and number of bone exposures were recorded. The data obtained were subjected to analysis of variance (ANOVA), the Mann-Whitney U-test, and multivariate logistic regression analysis.

Results: A total of 57.6% of the patients presented single bone exposure, 25.4% presented two, and 17% more than two exposures. The mean exposure size was 2.3±1.9 cm. Neither the bivariate analysis nor the multivariate multiple regression analysis found coadjuvant antineoplastic treatment to exert a statistically significant effect upon the number and size of bone exposures. On the other hand, there were statistically significant differences among the three study groups in relation to the CAO index (p=0.02) and the number of missing teeth (p=0.00). The resting whole saliva and stimulated whole saliva levels were similar in the three groups, though the patients with osteonecrosis of the jaws showed comparatively lower SWS levels.

Conclusions: Coadjuvant antineoplastic treatment alone appears to exert no influence upon the size and number of bone exposures in iBRONJ. The patients with this disease show a higher CAO index and a larger number of missing teeth.

Key words: Osteonecrosis of the jaws, bisphosphonates, bone exposure, CAO index, resting whole saliva, stimulated whole saliva.
Introduction
Osteonecrosis of the jaws is a form of chronic and slow-evolving osteomyelitis with no tendency towards spontaneous healing. The most widely known clinical form is osteoradionecrosis, a form of osteomyelitis associated to radiotherapy (1). Since the year 2003, a new form of osteonecrosis has been described, referred to as bisphosphonate-related osteonecrosis of the jaws (BRONJ), which is defined as the presence of necrotic bone exposed within the oral cavity for over 6-8 weeks in patients receiving or who have received treatment with bisphosphonates (BPs), and who have not undergone radiotherapy in the cervicofacial region (2,3). Instead of necrotic bone exposure, the disease in some cases is characterized by mucosal ulceration and symptoms - usually pain and suppuration, and even orosinusual communications and pathological fractures. This condition is also regarded as bisphosphonate-related osteonecrosis of the jaws (4,5).

The pathogenesis of BRONJ is not fully understood. The most widely accepted hypothesis refers to the existence of an alteration in physiological bone remodeling secondary to intense inhibition of the osteoclasts. Bisphosphonates inhibit osteoclast reabsorption activity by blocking 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA), the enzyme in charge of osteoclast protein prenylation (6). The appearance of cases of BRONJ in patients receiving treatment with denosumab (7), an anti-RANK ligand monoclonal antibody, confirms the theory that osteoclast inhibition is the triggering event underlying BRONJ (8). The BPs have also been attributed with certain antiangiogenic and antitumor effects (9).

BRONJ has very characteristic clinical manifestations that allow it to be easily identified from first contact with the patient (10). Major risk factors for BRONJ are the potency and duration of intravenous BP treatment, particularly with zoledronic acid, and dentoalveolar surgery – fundamentally extractions (11). Other treatments commonly administered to cancer patients, such as corticosteroids, immunosuppressors and hormone therapy, may also increase the risk of suffering BRONJ (12). It has been suggested that certain polymorphisms of the CYP2C8 gene could induce a degree of genetic susceptibility towards BRONJ, though this finding has not been confirmed by other studies (13).

The great majority of authors and expert panels agree on the importance of preventing BRONJ through the establishment and maintenance of adequate buccodental health (2,3,14,15). A rapid and simple method for assessing buccodental health is the CAO index, described by Klein, Palmer and Knutson (16), and adopted by the World Health Organization (WHO) for the conduction of oral health surveys, with the measurement of present and past caries in an individual or population.

Considering the natural tendency of intravenous BRONJ lesions to progress and spread over time (Fig. 1), the

Fig. 1. Images of one same patient with multiple bone exposure sites, corresponding to intravenous bisphosphonate-related osteonecrosis of the jaws.
first objective of the present study was the evaluation of whether coadjuvant antineoplastic treatment such as corticosteroids, thalidomide, interferon and hormones can influence the number and size of bone exposures. On the other hand, we have only found one publication comparing the buccodental conditions of patients receiving treatment with intravenous bisphosphonates versus those of patients who have already developed osteonecrosis of the jaws (17). Our second objective therefore has been the analysis and comparison of buccodental health and of the resting whole saliva and stimulated whole saliva levels in a group of patients with iBRONJ versus a group of patients administered BP via the intravenous route but who do not present BRONJ, and uncontrol group of healthy patients.

Material and Methods
All patients were seen in the Department of Stomatology and Maxillofacial Surgery (Valencia University General Hospital, Valencia, Spain) during the period between March 2006 and July 2009, in collaboration with the Departments of Hematological Oncology of Valencia University Clinic Hospital, La Fe University Hospital and Valencia University General Hospital (Valencia, Spain). Informed consent was obtained in all cases, and the study was approved by the Clinical Research Ethics Committee of Valencia University General Hospital. The study sample consisted of 156 patients, 105 women (67.3%) and 51 men (32.7%), with a mean age (± SD) of 62.3±10.9 years. Three groups were established:
- Group A: 67 patients administered intravenous bisphosphonates and who developed iBRONJ: 39 women and 28 men, with a mean age of 63.7 ± 11.6 years.
- Group B: 53 patients administered intravenous bisphosphonates but without BRONJ: 37 women and 16 men, with a mean age of 60.3±10.9 years.
- Group C: 36 healthy controls matched for age and gender to the other two groups.

Data were collected referred to the background malignancy, iBRONJ and buccodental condition. For the clinical exploration we used an intraoral mirror and an exploratory probe. The diagnosis of BRONJ was based on the corresponding clinical and radiological criteria (2,3,12). Samples of resting whole saliva (RWS) and stimulated whole saliva (SWS) were collected. Saliva measurement was not possible in 28 patients in group A. In the remaining 128 patients, saliva samples were collected as described below:

| Malignancy | BP administered | Time on BP (months) |
|------------|-----------------|---------------------|
|            | MM* BC* Zol* Pam* Zol+Pam |                     |
| Group A    | 43.3% 41.8% 66.2% 2% 31.8% | 32.2±17.6*          |
| Group B    | 49% 41.2% 100% - - | 22.5±10.8*          |

* MM: Multiple myeloma • BC: Breast cancer • Zol: Zoledronic acid • Pam: Pamidronate • Mean ± SD.
Results
-Number and size of bone exposures
A total of 57.6% of the patients presented single bone exposure, 25.4% presented two, 5.1% three, 10.2% four, and 1.7% presented 8 exposures (Fig. 2). The mean exposure size was 2.3±1.9 cm (median 2 cm). In the bi variate analysis, none of the coadjuvant antineoplastic treatments considered (corticosteroids, thalidomide, interferon and hormones) were significantly related to either the size or number of exposures (Table 2). In turn, in none of the logistic regression analysis models was coadjuvant antineoplastic treatment able to explain and predict the total size or number of exposures.

-CAO index
The mean CAO index (ICAO) for the total sample was 14.7. In group A (BRONJ) the mean ICAO was 16.8, versus 12.5 in group B (without BRONJ) and 13.4 in group C (control). The difference in ICAO distribution in the three groups was statistically significant (p=0.02).

On analyzing ICAO more in detail, the global mean number of caried teeth was found to be 1.6, with individualized values of 1.7, 1.8 and 0.8 for groups A, B and C, respectively. These differences were not statistically significant (p>0.05). The global mean number of missing teeth was 10.7. Statistically significant differences were observed in the mean number of missing teeth among the three study groups: 14.3 in group A, 6.8 in group B and 9.1 among the controls (group C) (p=0.00).

Lastly, the global mean number of filled teeth was 3.4. No statistically significant differences were observed in the mean number of filled teeth among the groups: 3.1 in group A, 3.8 in group B and 3.4 in group C (p>0.05). The results referred to the CAO index and its variables are summarized in table 3.

---

Table 2. Results of the bivariate analysis (Mann-Whitney U-test) of the number and size of bone exposures.

| Variables   | Mann-Whitney U-test results | p-value |
|-------------|-----------------------------|---------|
|             | Number of exposures         | Exposure size |
| Corticosteroids | 0.118                      | 0.189   |
| Thalidomide   | 0.991                       | 0.991   |
| Interferon    | 0.81                        | 0.121   |
| Hormones      | 0.07                        | 0.78    |
-Resting whole saliva (RWS) and stimulated whole saliva (SWS)

The global mean amount of RWS obtained in the 128 patients was 1.1 ml saliva/5 minutes. In group A (BRONJ) the mean amount was 1.3 ml/5 minutes, versus 1.1 ml/5 minutes in group B (without BRONJ), and 1 ml/5 minutes in group C (controls). In turn, the global mean amount of SWS obtained was 3.1 ml saliva/5 minutes. In group A the mean amount was 2.7 ml/5 minutes, versus 3.2 ml/5 minutes in group B, and 3.3 ml/5 minutes in group C. No statistically significant differences were found on comparing the mean amounts of RWS and SWS obtained in each group (p>0.05) (Table 4).

**Table 4.** Mean values in each study group corresponding to resting whole saliva (RWS) and stimulated whole saliva (SWS).

|                | Group A | Group B | Group C | ANOVA     | Significance |
|----------------|---------|---------|---------|-----------|-------------|
| RWS (ml/5’)   | 1.3     | 1.1     | 1       | F=0.954   | p>0.05      |
| SWS (ml/5’)   | 2.7     | 3.2     | 3.3     | F=1.2     | p>0.05      |

Discussion

The two main disorders associated to prolonged bisphosphonate therapy are BRONJ and pathological femoral fracture (18). The apparently exclusive location of BRONJ in the oral cavity, and specifically in jaw bone, appears to be related to the fact that this bone has a high turnover rate, which favors the accumulation of large amounts of bisphosphonates (19). The main risk factors for BRONJ are prolonged intravenous bisphosphonate therapy involving high-potency drugs, dentoalveolar surgical procedures, poorly fitting dental prostheses and intraoral trauma (20). Other factors that have also been related to BRONJ are chemotherapy, antiangiogenic drugs such as thalidomide, diabetes mellitus, corticosteroids, genetic susceptibility and deficient oral hygiene (21).

The different published series on osteonecrosis of the jaws generally do not describe the number or size of the bone exposure sites. At most, mention is made of the location of exposure in the upper or lower jaw, or both (22,23). We have found only three studies, published by Bagán et al. (1,10,11), in which express mention is made of the number of areas of exposed bone and their global mean size.

More than one-half of our patients (57.6%) presented a single bone exposure site, while 25.4% had two and 17% presented more than two exposures. This latter subgroup included patients with up to 8 iBRONJ exposure sites. According to Thumbigere-Math et al. (24), 80% of all spontaneously manifesting iBRONJ lesions measure 1 cm or less in diameter, and a little over one-half of the lesions appearing after a dental procedure (56.3%) have these same dimensions (i.e., 1 cm or less).

In our series, 50% of the patients presented a lesion size of between 1-3 cm, though there were two individuals with an unusually large lesion (7 cm), and one patient with an extreme lesion size of 10 cm. It should be underscored that on the basis of our findings, coadjuvant antineoplastic treatment alone exerted no influence upon the size and number of osteonecrosis areas in the context of iBRONJ.

A greater CAO index and a larger number of missing teeth were found in the patients with iBRONJ (p<0.05). The study published by Carmagnola et al. (17), which did not include a control group, reported no statistically significant differences in either the CAO index or in residual periodontal support between 20 patients with iBRONJ and 19 patients subjected to intravenous bisphosphonates without BRONJ. In that same publication, 50% of the patients with iBRONJ had a history of tooth extraction, versus 26.3% of the subjects without BRONJ. In our series, 73.1% of the patients in group A (BRONJ) had undergone tooth extraction, versus only 9.4% of those in group B (without BRONJ). These figures are similar to those recorded in the first published series on osteonecrosis of the jaws, in which 77% of the patients had undergone dental extraction (23). Likewise, Boonyapakorn et al. (25), in a study of 80 patients with BRONJ, found 77% of them to have a history of extraction. We found no statistically significant differences among the three groups in terms of the number of caried teeth or the number of filled teeth (p>0.05), though both caried and filled teeth were more prevalent in group B. The RWS levels were practically the same in all three groups (p>0.05). Certain differences were observed in the case of SWS, with lesser levels among the patients with BRONJ – though statistical significance was not reached.
At the time of intraoral exploration and collection of the saliva samples, 94% of the patients with BRONJ were receiving chemotherapy – a percentage that dropped to 68% in the case of group B (without BRONJ). These data could partially account for the observed differences among the study groups as regards buccodental condition. The fact that the patients with BRONJ had a longer duration of treatment with bisphosphonates, and the concomitant administration of chemotherapy, could have influenced the existence of oral cavity disorders such as diminished salivary gland function, increased susceptibility to fungal, viral and bacterial infections, and pro-pathogenic changes in the oral microflora (26,27). The greater number of missing teeth among the patients in group A might be related to the above. A growing number of studies underscore the beneficial effects of oral health prevention and maintenance strategies in patients programmed for or who are already receiving intravenous bisphosphonate therapy (28,29). In relation to BRONJ, we feel that studies addressing the buccodental health of these patients are required.

**Conclusion**

Coadjuvant antineoplastic treatment alone appears to exert no influence upon the size and number of exposed bone sites in the context of i.v. BRONJ – the patients with this disease in turn showing a comparatively greater CAO index and a larger number of missing teeth.

**References**

1. Bagan JV, Jiménez Y, Hernández S, Murillo J, Diaz JM, Poveda R, et al. Osteonecrosis of the jaws by intravenous bisphosphonates and osteoradionecrosis: a comparative study. Med Oral Patol Oral Cir Bucal. 2009;14:e616-9.
2. Bagan J, Blade J, Cozar JM, Constela M, García Sanz R, Gómez Veiga F, et al. Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates. Med Oral Patol Oral Cir Bucal. 2007;12:e336-40.
3. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, et al. Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. Am J Med. 2010;123:1060-4.
4. Bagan JV, Hens-Aumente E, Leopoldo-Rodado M, Poveda-Ro da R, Bagan L. Bisphosphonate-related osteonecrosis of the jaws: study of the staging system in a series of clinical cases. Oral Oncol. 2012;48:753-7.
5. Fedele S, Porter SR, D’Aciotto F, Aljohani S, Vescovi P, Manfredi M, et al. Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. Med Oral Patol Oral Cir Bucal. 2009;14:e616-9.
6. Bagan JV, Jiménez Y, Diaz JM, Murillo J, Sanchis JM, Poveda R, et al. Osteonecrosis of the jaws in intravenous bisphosphonate use: Proposal for a modification of the classical classification. Oral Oncol. 2009;45:645-6.
7. Aghaloo TL, Felsenfeld AL, Tetradis S. Osteonecrosis of the jaw in a patient on Denosumab. J Oral Maxillofac Surg. 2010;68:959-63.
8. Ruggiero SL. Bisphosphonate-related osteonecrosis of the jaw: an overview. Ann N Y Acad Sci. 2011;1218:38-46.
9. Gómez-Font R, Martínez-García ML, Olmos-Martínez JM. Os tochemonecrosis of the jaws due to bisphosphonate treatments. Med Oral Patol Oral Cir Bucal. 2008;13:E18-24.
10. Bagan JV, Murillo J, Jiménez Y, Poveda R, Milián MA, Sanchis JM, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med. 2005;34:120-3.
11. Bagan JV, Jiménez Y, Murillo J, Hernandez S, Poveda R, Sanchis JM, et al. Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases. Oral Oncol. 2006;42:327-9.
12. Siddiqui A, Payne AG, Zafar S. Bisphosphonate-induced osteonecrosis of the jaw: a medical enigma? Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;108:e1-8.
13. Such E, Cervera J, Terpos E, Bagan JV, Avaria A, Gómez I, et al. CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma. Haematologica. 2011;96:1557-9.
14. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65:369-76.
15. Ponte Fernández N, Estefanía Fresco R, Aguirre Urizar JM. Bis phosphonates and oral pathology I. General and preventive aspects. Med Oral Patol Oral Cir Bucal. 2006;11:E396-400.
16. Knutson JW. Workshop in dental health planning; present status of preventive procedures. J Or State Dent Assoc. 1947;16:34-43.
17. Carmagnola D, Celestino S, Abati S. Dental and periodontal history of oncologic patients on parenteral bisphosphonates with or without osteonecrosis of the jaws: a pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;106:e10-5.
18. Compston J. Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw. Osteoporos Int. 2011;22:2951-61.
19. Dickinson M, Prince HM, Kirsia S, Zannettino A, Gibbs SD, Mileskhill L, et al. Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment. Intern Med J. 2009;39:304-16.
20. Migliorati CA, Epstein JB, Abt E, Benerson JR. Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review. Nat Rev Endocrinol. 2011;7:34-42.
21. Sardella A, Carrassi A, Tarozzi M, Lodi G. Bisphosphonate-related osteonecrosis of the jaws associated with photodynamic therapy. J Oral Maxillofac Surg. 2011;69:e314-6.
22. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsen berg D, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22:1479-91.
23. Marx RE. Paimdonate (Arendia) and zolodronate (Zometa) induced avascular necrosis of the jaw: a growing epidemic. Oral Maxillofac Surg. 2005;6:1115-7.
24. Thumbeier-Math V, Sabino MC, Gopalkrishnan R, Hackabaty S, Dudek AZ, Basu S, et al. Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients. J Oral Maxillofac Surg. 2009;67:1904-13.
25. Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol. 2008;44:857-69.
26. Jensen SB, Mouridsen HT, Bergmann OJ, Reibel J, Brünner N, Nauntofte B. Oral mucosal lesions, microbial changes, and taste disturbances induced by adjuvant chemotherapy in breast cancer patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;106:217-26.
27. Napeñas JJ, Brennan MT, Coleman S, Kent ML, Noll J, Fren ette G, et al. Molecular methodology to assess the impact of cancer chemotherapy on the oral bacterial flora: a pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003;95:34-42.
28. Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Mileshkin L, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid. Ann Oncol. 2009;20:117-20.
29. Nicolatou-Galitis O, Papadopoulou E, Sarri T, Boziari P, Kara yianni A, Kyrtsonis MC, et al. Osteonecrosis of the jaw in oncology.
patients treated with bisphosphonates: prospective experience of a dental oncology referral center. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;112:195-202.

Acknowledgments
This study was sponsored by Novartis®.

Conflicts of interest
The authors declare no conflicts of interest in relation to the study or the results obtained.